[1, 2, 4] triazolo [1, 5-c] quinazolin-5-amines J Lefranc, N Schmees, L Zorn, RM Meier, SA Herbert, J Günther, I Gutcher, ... US Patent App. 17/634,930, 2023 | | 2023 |
2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists J Lefranc, N Schmees, U Röhn, L Zorn, J Günther, I Gutcher, L Röse, ... US Patent 11,304,946, 2022 | | 2022 |
2-heteroaril-3-okso-2, 3-dihidropiridazin-4-karboksamidai, skirti vėžio gydymui I GUTCHER, R Ulrike, N Schmees, L Zorn, R Lars, B Bader, C KOBER, ... | | 2021 |
2-heteroaril-3-okso-2, 3-dihidropiridazin-4-karboksamidi za liječenje raka I Gutcher, R Ulrike, N Schmees, L Zorn, R Lars, B Bader, C Kober, ... HR Patent App. P20210143T T, 2021 | | 2021 |
2-heteroaril-3-oxo-2, 3-dihidropiridazin-4-carboxamidas N Schmees, I Gutcher, H Irlbacher, B Bader, D Stockigt, L Rose, L Zorn, ... | | 2019 |
2-heteroaril-3-oxo-2, 3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer B Bader, L Zorn, N Schmees, H Irlbacher, I Gutcher, M Platten, U Röhn, ... | | 2019 |
2-Heteroaril-3-oxo-2, 3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer I Gutcher, U Röhn, N Schmees, L Zorn, L Röse, B Bader, C Kober, ... ES Patent App. 18,703,958 T, 2021 | | 2021 |
2-heteroaril-3-oxo-2, 3-dihidropiridazin-4-carboxamidas. L Zorn, B Bader, H Irlbacher, I Gutcher, U Röhn, N Schmees, L Röse, ... | | 2020 |
2-heteroaryl-3-oxo-2, 3-dihydropyridazin-4-carboxamider til behandling af cancer I Gutcher, U Röhn, N Schmees, L Zorn, L Röse, B Bader, R Carretero, ... | | 2021 |
2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer I Gutcher, N Schmees, L Röse, B Bader, C Kober, R Carretero, D Stöckigt, ... US Patent 11,795,164, 2023 | | 2023 |
2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer U Rohn, N Schmees, L Zorn, R Karretero, L Rose, B Bader, C Kober, ... | | 2021 |
2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer I Gutcher, R Ulrike, N Schmees, L Zorn, R Lars, B Bader, C Kober, ... | 1 | 2018 |
2-hétéroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides pour le traitement du cancer N Schmees, L Röse, L Zorn, U Röhn, D Stöckigt, B Bader, H Irlbacher, ... | | 2021 |
2-phenylpyrimidine-4-carboxamides as AHR inhibitors J Lefranc, N Schmees, U Röhn, L Zorn, J Günther, I Gutcher, L Röse, ... US Patent 11,524,944, 2022 | 1 | 2022 |
2320P Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma P Horak, J Becker, S Blobner, D Weber, S Uhrig, J Förster, A Raveendran, ... Annals of Oncology 34, S1185, 2023 | | 2023 |
3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamides N Schmees, I Gutcher, H Irlbacher, B Bader, N Zhao, M Platten, U Röhn, ... US Patent 11,040,035, 2021 | 1 | 2021 |
3-oxo-6-heteroaryl-2-phenyl-2, 3-dihydropyridazine-4-carboxamides I Gutcher, U Röhn, L Zorn, L Röse, B Bader, C Kober, R Carretero, ... US Patent 11,591,311, 2023 | | 2023 |
3, 4-DAA, an orally active synthetic tryptophan catabolite, treats established autoimmune neuroinflammation M Platten, P Ho, S Youssef, H Garren, P Fontoura, R Sobel, M Selley, ... Aktuelle Neurologie 32 (S 4), P579, 2005 | | 2005 |
352 Targeting glioblastoma with a TCR specific to the HLA-A* 02-restricted, glioblastoma-associated antigen PTPRZ1 YC Chih, P Koopmann, AC Dietsch, DA Agardy, A De Roia, A Kourtesakis, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
374 Discovery of mutant IDH1 reactive T cell receptors for transgenic T cell therapy J Michel, K Sanghvi, K Lindner, A Dietsch, K Jähne, T Bunse, W Wick, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |